PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells

ABSTRACT: TiO2-enriched and non-enriched samples and a pooled TiO2-enriched alkaline phosphatase treated sample from subconfluent A549 lung adenocarcinoma cells line. Cells were subjected to on of the 6 different treatments: Control sample, RNAi mediated depletion of PPP2R1A, CIP2A, or PME-1, and treatment with 100nM Trametinib for 20 hours for control and PPP2R1A depleted cells. Each condition was performed in triplicates with different siRNA sequences.

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Epithelial Cell

SUBMITTER: Laxman Yetukuri  

LAB HEAD: Jukka Westermarck (lab head) Laxman yetukuri (submitted)

PROVIDER: PXD009900 | Pride | 2018-10-11

REPOSITORIES: Pride